Luminary Therapeutics is a clinical-stage biotechnology company developing next-generation CAR T-cell therapies for cancer and autoimmune diseases. Its proprietary Gamma 2.0+ platform uses non-viral, allogeneic engineering to enable scalable, off-the-shelf treatments at a fraction of current costs. CEO Jeff Liter is a serial entrepreneur leading the company’s operations from the Virginia Tech Corporate Research Center. Lunch Pail Ventures invested in Luminary Therapeutics in April 2025.